Dr. William Sikov on Triple-Negative Breast Cancer Patients Not Responding to Treatment

Publication
Video
Special ReportsBreast Cancer (Issue 2)
Volume 1
Issue 2

William Sikov, MD, associate director of Clinical Research, Program in Women

William Sikov, MD, associate director of Clinical Research, Program in Women’s Oncology, Women and Infants Hospital of Rhode Island, on the phase II CALGB 40603 trial, which tested if standard neoadjuvant chemotherapy plus carboplatin and/or bevacizumab would result in a pathologic complete response in patients with stage II/III triple-negative breast cancer.

Articles in this issue
Glembatumumab and the Phase IIb Registrational METRIC Trial: Q&A With Denise Yardley, MD, and Linda Vahdat, MD
Glembatumumab and the Phase IIb Registrational METRIC Trial: Q&A With Denise Yardley, MD, and Linda Vahdat, MD
Survival Improved Over 10 Years With Breast-Conserving Therapy Versus Mastectomy
Survival Improved Over 10 Years With Breast-Conserving Therapy Versus Mastectomy
Dr. Carey Anders on Treating Brain Metastases in Breast Cancer
Dr. Carey Anders on Treating Brain Metastases in Breast Cancer
Dr. William Sikov on Triple-Negative Breast Cancer Patients Not Responding to Treatment
Dr. William Sikov on Triple-Negative Breast Cancer Patients Not Responding to Treatment
Dr. Matthew J. Ellis on Neoadjuvant Palbociclib in Primary Breast Cancer
Dr. Matthew J. Ellis on Neoadjuvant Palbociclib in Primary Breast Cancer
Avelumab Shows Efficacy in PD-L1-Positive Metastatic Breast Cancer
Avelumab Shows Efficacy in PD-L1-Positive Metastatic Breast Cancer
The Complications and Costs in Mastectomies and Lumpectomies in Early Breast Cancer
The Complications and Costs in Mastectomies and Lumpectomies in Early Breast Cancer
Study Links pCR Post-Neoadjuvant Therapy to Increased Survival Rates in TNBC
Study Links pCR Post-Neoadjuvant Therapy to Increased Survival Rates in TNBC
Recent Videos
Related Content
FDA Grants Breakthrough Status to DCISionRT Test in DCIS

FDA Grants Breakthrough Status to DCISionRT Test in DCIS

Jordyn Sava
January 23rd 2025
Article

The FDA has granted breakthrough therapy designation to the DCISionRT test, a tool that assesses radiation therapy benefit for women aged 30 to 85 with ductal carcinoma in situ.

Read More

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Jordyn Sava;Sanjay K. Juneja, MD
January 15th 2025
Podcast

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

Listen

Can ChatGPT Prove Its Effectiveness in Health Care?

Can ChatGPT Prove Its Effectiveness in Health Care?

Grace Koennecke
January 19th 2025
Article

A study by UVA Health found that while ChatGPT Plus holds potential for enhancing diagnoses, physicians need better training to use AI effectively.

Read More

Unpacking the New Recommendations for Early-Stage Breast Cancer Management

Unpacking the New Recommendations for Early-Stage Breast Cancer Management

April 15th 2022
Podcast

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

Listen

Emerging BsAbs and Their Impact in Multiple Myeloma

Emerging BsAbs and Their Impact in Multiple Myeloma

Morgan Bayer
January 17th 2025
Article

Bispecific antibody therapy is transforming cancer treatment, especially in multiple myeloma, with ongoing studies exploring early-line and maintenance use.

Read More

Conservative Management Is on the Rise in Intermediate-Risk Prostate Cancer

Conservative Management Is on the Rise in Intermediate-Risk Prostate Cancer

Jonah Feldman
January 17th 2025
Article

In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year rise in active surveillance and watchful waiting in patients with intermediate-risk prostate cancer.

Read More